申请人:BASF Aktiengesellschaft
公开号:US05296485A1
公开(公告)日:1994-03-22
Substituted N-phenylpiperidines I ##STR1## (R.sup.1 =H, NO.sub.2, CN, halogen, C.sub.1 -C.sub.4 -alkyl, CF.sub.3, OCF.sub.3, OH, CH.sub.2 OH, COOH, CHO, NH--CHO, NH.sub.2, CO--NH.sub.2, 5-tetrazinyl, R.sup.4 --O--, R.sup.4 --O--CH.sub.2 --, R.sup.4 O--CO--, R.sup.4 --CO--, R.sup.4 --NH--CO, R.sup.4 --CO--NH--, R.sup.4 --SO.sub.2 --NH--; R.sup.2 =H, NO.sub.2, halogen, C.sub.1 -C.sub.4 -alkyl or R.sup.4 --O--; ##STR2## R.sup.4 =C.sub.1 -C.sub.4 -alkyl or phenyl which can carry one of the R.sup.2 radicals; R.sup.5, R.sup.6 =H or one of the R.sup.4 radicals; R.sup.7 =one of the R.sup.1 radicals; n=0 or 1; m=1 or 2; with the proviso that R.sup.3 is ##STR3## only when n is 1, and the optical isomers in the case of optical isomerism, and the physiologically tolerated acid addition salts, are suitable as drugs.
取代N-苯基哌啶化合物I(其中R.sup.1 =H、NO.sub.2、CN、卤素、C.sub.1-C.sub.4-烷基、CF.sub.3、OCF.sub.3、OH、CH.sub.2OH、COOH、CHO、NH--CHO、NH.sub.2、CO--NH.sub.2、5-四唑基、R.sup.4 --O--、R.sup.4 --O--CH.sub.2--、R.sup.4 O--CO--、R.sup.4 --CO--、R.sup.4 --NH--CO、R.sup.4 --CO--NH--、R.sup.4 --SO.sub.2--NH--; R.sup.2 =H、NO.sub.2、卤素、C.sub.1-C.sub.4-烷基或R.sup.4 --O--; R.sup.4 =C.sub.1-C.sub.4-烷基或苯基,可以携带R.sup.2基团之一;R.sup.5、R.sup.6 =H或R.sup.4基团之一;R.sup.7 =R.sup.1基团之一;n=0或1;m=1或2;但R.sup.3是##STR3##时仅当n为1时,且在光学异构体情况下的光学异构体和生理上可耐受的酸盐加合物均适用作药物。